NSG 527 Midterm Exam Prep Document | 2026/2027 Edition |
150 Verified Questions
NSG 527 Midterm Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document for NSG 527 (Psychopathology, Theories, &
Advanced Clinical Modalities) at Wilkes University contains 150 verified questions and answers,
meticulously aligned with the 2026/2027 curriculum. Each question is accompanied by a detailed
rationale to reinforce key concepts in advanced psychiatric nursing. The content covers major
theoretical frameworks, diagnostic criteria, and evidence-based interventions essential for midterm
success. Updated to reflect the latest DSM-5-TR guidelines and contemporary clinical practices, this
resource ensures students are thoroughly prepared for the exam.
Key Features:
Theoretical foundations of psychopathology (psychodynamic, cognitive-behavioral, biological)
Advanced clinical modalities including psychotherapy, pharmacotherapy, and integrative approaches
DSM-5-TR diagnostic criteria for major psychiatric disorders
Therapeutic communication and patient assessment techniques
Ethical and legal considerations in psychiatric nursing
Case-based application of treatment planning and intervention strategies
Updates for 2026:
- Incorporated DSM-5-TR revisions for neurodevelopmental and trauma-related disorders
- Added new questions on telepsychiatry and digital health modalities
- Updated pharmacological content to reflect 2026 FDA approvals and black box warnings
- Expanded coverage of cultural competence and health equity in psychiatric care
- Revised rationales to include recent meta-analyses and clinical practice guidelines
Abstract:
This document serves as a definitive study guide for the NSG 527 Midterm Exam, focusing on psychopathology,
theoretical models, and advanced clinical modalities. It integrates core concepts from biological, psychological,
and sociocultural perspectives to provide a holistic understanding of mental health disorders. The 150 verified
questions are organized by content area, each with detailed answers and rationales that elucidate correct and
incorrect options. Emphasis is placed on differential diagnosis, evidence-based treatment selection, and
therapeutic alliance building. The material is updated to align with the 2026/2027 academic year, incorporating
the latest DSM-5-TR criteria and emerging trends in psychiatric nursing. This resource is designed to promote
critical thinking and clinical reasoning, ensuring students achieve a graded A+ performance on the midterm
examination.
Keywords:
NSG 527, psychopathology, advanced clinical modalities, DSM-5-TR, psychiatric nursing, theoretical frameworks,
midterm exam, Wilkes University
Answer Format:
Each question is followed by the correct answer in bold, with a comprehensive rationale explaining why the correct
answer is right and why the distractors are incorrect. Rationales include references to DSM-5-TR criteria,
therapeutic modalities, and evidence-based practice guidelines to facilitate deep learning.
Compliance Checklist:
Aligned with Wilkes University NSG 527 course objectives and syllabus
Page 1
, Updated to 2026/2027 academic year standards
Incorporates DSM-5-TR diagnostic criteria and coding
Reflects current American Nurses Association (ANA) psychiatric-mental health nursing scope and standards
Includes ethical and legal considerations per HIPAA and state regulations
Verified for accuracy by subject matter experts
Content Area Overview:
Content Area Questions Key Topics Weight
Theoretical Foundations of 1-30 Psychodynamic theory, cognitive-behavioral 20%
Psychopathology theory, biological models, biopsychosocial
model, attachment theory
Diagnostic Criteria and 31-60 DSM-5-TR structure, neurodevelopmental 20%
Classification disorders, schizophrenia spectrum, mood
disorders, anxiety disorders
Advanced Clinical Modalities 61-90 Psychotherapy approaches (CBT, DBT, 20%
psychodynamic), pharmacotherapy, ECT,
TMS, integrative therapies
Assessment and Therapeutic 91-120 Mental status exam, risk assessment, 20%
Communication motivational interviewing, therapeutic
rapport, cultural formulation
Ethical, Legal, and Professional 121-150 Informed consent, confidentiality, 20%
Issues mandatory reporting, boundary issues,
interdisciplinary collaboration
Page 2
,Q1. A patient with a history of major depressive disorder and generalized anxiety disorder presents with
persistent anhedonia, psychomotor retardation, and excessive worry. Current medications include sertraline
200 mg daily and bupropion 300 mg daily. Despite adherence for 8 weeks, symptoms have not improved.
Which neurobiological mechanism most likely underlies this treatment resistance?
A. Overactivation of the hypothalamic-pituitary-adrenal (HPA) axis with elevated cortisol levels leading to
hippocampal atrophy
B. Polymorphism in the serotonin transporter gene (5-HTTLPR) resulting in reduced synaptic serotonin
availability
C. Dysregulation of glutamatergic signaling with reduced NMDA receptor function in the prefrontal cortex
D. Decreased dopaminergic transmission in the mesolimbic pathway due to chronic stress-induced
downregulation of D2 receptors
Correct Answer: A. Overactivation of the hypothalamic-pituitary-adrenal (HPA) axis with elevated cortisol
levels leading to hippocampal atrophy
Rationale: Treatment-resistant depression in the context of high-dose sertraline and bupropion often involves HPA
axis dysregulation with hypercortisolemia, which can cause hippocampal atrophy and impair response to standard
antidepressants. Option A is correct because chronic stress and depression lead to HPA axis overactivity, reducing
neuroplasticity and treatment efficacy. Option B is less specific as 5-HTTLPR polymorphism affects initial response
but not necessarily resistance after adequate dosing. Option C is associated with ketamine response, not typical
SSRI/SNRI resistance. Option D is relevant to reward circuitry but not the primary driver of resistance in this
presentation.
Why Wrong:
B - 5-HTTLPR polymorphism influences initial antidepressant response but does not fully explain resistance
after 8 weeks of high-dose therapy.
C - Glutamatergic dysregulation is more implicated in rapid-acting antidepressant mechanisms (e.g.,
ketamine) rather than SSRI/SNRI resistance.
D - Mesolimbic dopamine dysfunction contributes to anhedonia but is not the primary mechanism underlying
general treatment resistance to SSRIs and bupropion.
Reference: Nemeroff, C.B. (2020). The role of the hypothalamic-pituitary-adrenal axis in the pathophysiology of
depression. American Journal of Psychiatry, 177(5), 390-402.
Q2. A 30-year-old individual with a history of childhood emotional neglect presents with chronic feelings of
emptiness, unstable relationships, and impulsive behaviors. The patient reports a pattern of idealizing new
partners then devaluing them. Which theoretical framework best explains the development of this personality
structure?
A. Mahler's separation-individuation theory, with failure to achieve object constancy leading to splitting
B. Beck's cognitive triad, with negative schemas about self, world, and future formed from early rejection
C. Bowlby's attachment theory, with disorganized attachment resulting in contradictory internal working
models
D. Kernberg's object relations theory, with pathological internalization of aggressive and idealized self-object
representations
Correct Answer: D. Kernberg's object relations theory, with pathological internalization of aggressive and
idealized self-object representations
Rationale: The presentation is consistent with borderline personality disorder (BPD). Kernberg's object relations
theory posits that BPD arises from failure to integrate good and bad representations of self and others due to
excessive aggression and lack of soothing experiences, leading to splitting and identity diffusion. Option D directly
addresses this. Option A (Mahler) describes earlier developmental stages but is less specific to BPD's splitting.
Option B (Beck) is more applicable to depression. Option C (Bowlby) explains attachment patterns but does not
fully capture the internal object relations dynamics.
Why Wrong:
Page 3
, A - Mahler's theory focuses on separation-individuation in toddlerhood; while relevant, it does not
specifically account for pathological splitting and identity diffusion in BPD.
B - Beck's cognitive triad is primarily a model for depression, not for the pervasive identity and relational disturbances
seen in BPD.
C - Bowlby's attachment theory explains relational patterns but does not address the internal object relations and defense
mechanisms central to BPD.
Reference: Kernberg, O.F. (2016). Object relations theory and clinical psychoanalysis. Jason Aronson.
Q3. A patient with schizophrenia has been stabilized on clozapine 400 mg daily for 6 months but continues to
experience persistent negative symptoms, including social withdrawal and avolition. Which augmentation
strategy is most supported by current evidence?
A. Addition of aripiprazole 15 mg daily to enhance dopamine D2 partial agonism
B. Addition of memantine 20 mg daily to modulate glutamatergic transmission
C. Addition of fluoxetine 20 mg daily to increase serotonin availability
D. Addition of modafinil 200 mg daily to improve wakefulness and motivation
Correct Answer: B. Addition of memantine 20 mg daily to modulate glutamatergic transmission
Rationale: Negative symptoms in schizophrenia are linked to hypofunction of NMDA receptors and glutamatergic
dysfunction. Memantine, an NMDA receptor antagonist, has shown modest benefit for negative symptoms in some
studies when added to antipsychotics. Option B is the most evidence-supported. Option A (aripiprazole) is a partial
agonist but primarily targets positive symptoms; its efficacy for negative symptoms is limited. Option C (fluoxetine)
may exacerbate negative symptoms via serotonin-mediated dopamine inhibition. Option D (modafinil) may improve
wakefulness but lacks robust evidence for negative symptoms.
Why Wrong:
A - Aripiprazole primarily targets positive symptoms and has inconsistent evidence for negative symptom
improvement; it may even worsen negative symptoms in some patients.
C - SSRIs like fluoxetine can theoretically worsen negative symptoms by increasing serotonin, which inhibits
dopamine release in prefrontal cortex.
D - Modafinil is a wakefulness-promoting agent with limited and conflicting evidence for negative
symptoms; it is not a standard augmentation for schizophrenia.
Reference: Tandon, R., et al. (2017). Treatment of negative symptoms in schizophrenia: A systematic review.
Schizophrenia Research, 186, 3-14.
Q4. A patient with bipolar I disorder, currently in a depressive episode, has a history of severe mania with
psychotic features. Which of the following combination strategies is most appropriate for acute treatment
while minimizing risk of mood destabilization?
A. Lithium carbonate titrated to serum level of 0.8-1.2 mEq/L plus lamotrigine 200 mg daily
B. Olanzapine 10 mg daily plus fluoxetine 20 mg daily (symbyax)
C. Valproic acid 1000 mg daily plus quetiapine 300 mg daily
D. Carbamazepine 600 mg daily plus venlafaxine 150 mg daily
Correct Answer: B. Olanzapine 10 mg daily plus fluoxetine 20 mg daily (symbyax)
Rationale: For bipolar depression with history of severe mania, the combination of olanzapine and fluoxetine
(Symbyax) is FDA-approved and has demonstrated efficacy without high risk of switching to mania. Option B is
correct. Option A (lithium + lamotrigine) is effective but lamotrigine requires slow titration and is less potent for
acute depression. Option C (valproate + quetiapine) is used but quetiapine has a higher metabolic burden. Option
D (carbamazepine + venlafaxine) has higher risk of mood destabilization due to venlafaxine's potential to induce
mania.
Why Wrong:
A - Lamotrigine is effective for bipolar depression prophylaxis but requires slow titration and is not first-line
for acute episodes due to delayed onset.
Page 4
150 Verified Questions
NSG 527 Midterm Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document for NSG 527 (Psychopathology, Theories, &
Advanced Clinical Modalities) at Wilkes University contains 150 verified questions and answers,
meticulously aligned with the 2026/2027 curriculum. Each question is accompanied by a detailed
rationale to reinforce key concepts in advanced psychiatric nursing. The content covers major
theoretical frameworks, diagnostic criteria, and evidence-based interventions essential for midterm
success. Updated to reflect the latest DSM-5-TR guidelines and contemporary clinical practices, this
resource ensures students are thoroughly prepared for the exam.
Key Features:
Theoretical foundations of psychopathology (psychodynamic, cognitive-behavioral, biological)
Advanced clinical modalities including psychotherapy, pharmacotherapy, and integrative approaches
DSM-5-TR diagnostic criteria for major psychiatric disorders
Therapeutic communication and patient assessment techniques
Ethical and legal considerations in psychiatric nursing
Case-based application of treatment planning and intervention strategies
Updates for 2026:
- Incorporated DSM-5-TR revisions for neurodevelopmental and trauma-related disorders
- Added new questions on telepsychiatry and digital health modalities
- Updated pharmacological content to reflect 2026 FDA approvals and black box warnings
- Expanded coverage of cultural competence and health equity in psychiatric care
- Revised rationales to include recent meta-analyses and clinical practice guidelines
Abstract:
This document serves as a definitive study guide for the NSG 527 Midterm Exam, focusing on psychopathology,
theoretical models, and advanced clinical modalities. It integrates core concepts from biological, psychological,
and sociocultural perspectives to provide a holistic understanding of mental health disorders. The 150 verified
questions are organized by content area, each with detailed answers and rationales that elucidate correct and
incorrect options. Emphasis is placed on differential diagnosis, evidence-based treatment selection, and
therapeutic alliance building. The material is updated to align with the 2026/2027 academic year, incorporating
the latest DSM-5-TR criteria and emerging trends in psychiatric nursing. This resource is designed to promote
critical thinking and clinical reasoning, ensuring students achieve a graded A+ performance on the midterm
examination.
Keywords:
NSG 527, psychopathology, advanced clinical modalities, DSM-5-TR, psychiatric nursing, theoretical frameworks,
midterm exam, Wilkes University
Answer Format:
Each question is followed by the correct answer in bold, with a comprehensive rationale explaining why the correct
answer is right and why the distractors are incorrect. Rationales include references to DSM-5-TR criteria,
therapeutic modalities, and evidence-based practice guidelines to facilitate deep learning.
Compliance Checklist:
Aligned with Wilkes University NSG 527 course objectives and syllabus
Page 1
, Updated to 2026/2027 academic year standards
Incorporates DSM-5-TR diagnostic criteria and coding
Reflects current American Nurses Association (ANA) psychiatric-mental health nursing scope and standards
Includes ethical and legal considerations per HIPAA and state regulations
Verified for accuracy by subject matter experts
Content Area Overview:
Content Area Questions Key Topics Weight
Theoretical Foundations of 1-30 Psychodynamic theory, cognitive-behavioral 20%
Psychopathology theory, biological models, biopsychosocial
model, attachment theory
Diagnostic Criteria and 31-60 DSM-5-TR structure, neurodevelopmental 20%
Classification disorders, schizophrenia spectrum, mood
disorders, anxiety disorders
Advanced Clinical Modalities 61-90 Psychotherapy approaches (CBT, DBT, 20%
psychodynamic), pharmacotherapy, ECT,
TMS, integrative therapies
Assessment and Therapeutic 91-120 Mental status exam, risk assessment, 20%
Communication motivational interviewing, therapeutic
rapport, cultural formulation
Ethical, Legal, and Professional 121-150 Informed consent, confidentiality, 20%
Issues mandatory reporting, boundary issues,
interdisciplinary collaboration
Page 2
,Q1. A patient with a history of major depressive disorder and generalized anxiety disorder presents with
persistent anhedonia, psychomotor retardation, and excessive worry. Current medications include sertraline
200 mg daily and bupropion 300 mg daily. Despite adherence for 8 weeks, symptoms have not improved.
Which neurobiological mechanism most likely underlies this treatment resistance?
A. Overactivation of the hypothalamic-pituitary-adrenal (HPA) axis with elevated cortisol levels leading to
hippocampal atrophy
B. Polymorphism in the serotonin transporter gene (5-HTTLPR) resulting in reduced synaptic serotonin
availability
C. Dysregulation of glutamatergic signaling with reduced NMDA receptor function in the prefrontal cortex
D. Decreased dopaminergic transmission in the mesolimbic pathway due to chronic stress-induced
downregulation of D2 receptors
Correct Answer: A. Overactivation of the hypothalamic-pituitary-adrenal (HPA) axis with elevated cortisol
levels leading to hippocampal atrophy
Rationale: Treatment-resistant depression in the context of high-dose sertraline and bupropion often involves HPA
axis dysregulation with hypercortisolemia, which can cause hippocampal atrophy and impair response to standard
antidepressants. Option A is correct because chronic stress and depression lead to HPA axis overactivity, reducing
neuroplasticity and treatment efficacy. Option B is less specific as 5-HTTLPR polymorphism affects initial response
but not necessarily resistance after adequate dosing. Option C is associated with ketamine response, not typical
SSRI/SNRI resistance. Option D is relevant to reward circuitry but not the primary driver of resistance in this
presentation.
Why Wrong:
B - 5-HTTLPR polymorphism influences initial antidepressant response but does not fully explain resistance
after 8 weeks of high-dose therapy.
C - Glutamatergic dysregulation is more implicated in rapid-acting antidepressant mechanisms (e.g.,
ketamine) rather than SSRI/SNRI resistance.
D - Mesolimbic dopamine dysfunction contributes to anhedonia but is not the primary mechanism underlying
general treatment resistance to SSRIs and bupropion.
Reference: Nemeroff, C.B. (2020). The role of the hypothalamic-pituitary-adrenal axis in the pathophysiology of
depression. American Journal of Psychiatry, 177(5), 390-402.
Q2. A 30-year-old individual with a history of childhood emotional neglect presents with chronic feelings of
emptiness, unstable relationships, and impulsive behaviors. The patient reports a pattern of idealizing new
partners then devaluing them. Which theoretical framework best explains the development of this personality
structure?
A. Mahler's separation-individuation theory, with failure to achieve object constancy leading to splitting
B. Beck's cognitive triad, with negative schemas about self, world, and future formed from early rejection
C. Bowlby's attachment theory, with disorganized attachment resulting in contradictory internal working
models
D. Kernberg's object relations theory, with pathological internalization of aggressive and idealized self-object
representations
Correct Answer: D. Kernberg's object relations theory, with pathological internalization of aggressive and
idealized self-object representations
Rationale: The presentation is consistent with borderline personality disorder (BPD). Kernberg's object relations
theory posits that BPD arises from failure to integrate good and bad representations of self and others due to
excessive aggression and lack of soothing experiences, leading to splitting and identity diffusion. Option D directly
addresses this. Option A (Mahler) describes earlier developmental stages but is less specific to BPD's splitting.
Option B (Beck) is more applicable to depression. Option C (Bowlby) explains attachment patterns but does not
fully capture the internal object relations dynamics.
Why Wrong:
Page 3
, A - Mahler's theory focuses on separation-individuation in toddlerhood; while relevant, it does not
specifically account for pathological splitting and identity diffusion in BPD.
B - Beck's cognitive triad is primarily a model for depression, not for the pervasive identity and relational disturbances
seen in BPD.
C - Bowlby's attachment theory explains relational patterns but does not address the internal object relations and defense
mechanisms central to BPD.
Reference: Kernberg, O.F. (2016). Object relations theory and clinical psychoanalysis. Jason Aronson.
Q3. A patient with schizophrenia has been stabilized on clozapine 400 mg daily for 6 months but continues to
experience persistent negative symptoms, including social withdrawal and avolition. Which augmentation
strategy is most supported by current evidence?
A. Addition of aripiprazole 15 mg daily to enhance dopamine D2 partial agonism
B. Addition of memantine 20 mg daily to modulate glutamatergic transmission
C. Addition of fluoxetine 20 mg daily to increase serotonin availability
D. Addition of modafinil 200 mg daily to improve wakefulness and motivation
Correct Answer: B. Addition of memantine 20 mg daily to modulate glutamatergic transmission
Rationale: Negative symptoms in schizophrenia are linked to hypofunction of NMDA receptors and glutamatergic
dysfunction. Memantine, an NMDA receptor antagonist, has shown modest benefit for negative symptoms in some
studies when added to antipsychotics. Option B is the most evidence-supported. Option A (aripiprazole) is a partial
agonist but primarily targets positive symptoms; its efficacy for negative symptoms is limited. Option C (fluoxetine)
may exacerbate negative symptoms via serotonin-mediated dopamine inhibition. Option D (modafinil) may improve
wakefulness but lacks robust evidence for negative symptoms.
Why Wrong:
A - Aripiprazole primarily targets positive symptoms and has inconsistent evidence for negative symptom
improvement; it may even worsen negative symptoms in some patients.
C - SSRIs like fluoxetine can theoretically worsen negative symptoms by increasing serotonin, which inhibits
dopamine release in prefrontal cortex.
D - Modafinil is a wakefulness-promoting agent with limited and conflicting evidence for negative
symptoms; it is not a standard augmentation for schizophrenia.
Reference: Tandon, R., et al. (2017). Treatment of negative symptoms in schizophrenia: A systematic review.
Schizophrenia Research, 186, 3-14.
Q4. A patient with bipolar I disorder, currently in a depressive episode, has a history of severe mania with
psychotic features. Which of the following combination strategies is most appropriate for acute treatment
while minimizing risk of mood destabilization?
A. Lithium carbonate titrated to serum level of 0.8-1.2 mEq/L plus lamotrigine 200 mg daily
B. Olanzapine 10 mg daily plus fluoxetine 20 mg daily (symbyax)
C. Valproic acid 1000 mg daily plus quetiapine 300 mg daily
D. Carbamazepine 600 mg daily plus venlafaxine 150 mg daily
Correct Answer: B. Olanzapine 10 mg daily plus fluoxetine 20 mg daily (symbyax)
Rationale: For bipolar depression with history of severe mania, the combination of olanzapine and fluoxetine
(Symbyax) is FDA-approved and has demonstrated efficacy without high risk of switching to mania. Option B is
correct. Option A (lithium + lamotrigine) is effective but lamotrigine requires slow titration and is less potent for
acute depression. Option C (valproate + quetiapine) is used but quetiapine has a higher metabolic burden. Option
D (carbamazepine + venlafaxine) has higher risk of mood destabilization due to venlafaxine's potential to induce
mania.
Why Wrong:
A - Lamotrigine is effective for bipolar depression prophylaxis but requires slow titration and is not first-line
for acute episodes due to delayed onset.
Page 4
